- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05750134
Endoscopic Sleeve Gastroplasty for Moderate Obesity (PLICATURE)
March 3, 2023 updated by: Assistance Publique - Hôpitaux de Paris
Endoscopic Sleeve Gastroplasty for Overweight or Moderately Obese Patients: Identification of Predictive Factors for Weight Loss
Weight loss is of paramount importance to ameliorate obesity-related complications.
Endoscopic sleeve gastroplasty is a new therapeutic option to obtain significant weight reduction in obese patients.
Nevertheless, a only a part of patients experience sufficient weight loss to improve comorbidities.
A better understanding of mechanisms driving body weight trajectory after endoscopic sleeve gastroplasty may help patient selection and improve efficacy.
The main aim of this study is to identify factors associated with weight reduction after endoscopic sleeve gastroplasty in patients with overweight or morbid obesity without indication to bariatric surgery.
For this purpose, the investigators conduct a retro-prospective cohort study including patients with overweight or moderate obesity undergoing endoscopic sleeve gastroplasty between March 2017 and March 2023
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
The prevalence of obesity is increasing worldwide, and it is estimated that one quarter of the world's population will be overweight or obese by 2045.
Obesity can lead to complications, including cardiovascular damage (myocardial ischemia and stroke), liver damage (non-alcoholic steatohepatitis and liver cancer), diabetes and extra-hepatic cancers.
In this context, achievement of a significant long-term weight loss is of paramount importance to ameliorate patient outcome.
Bariatric surgery is the most effective treatment for severe obesity and results in a significant long-term weight loss.
However, bariatric surgery is restricted to patients with a BMI >40 kg/m2 or >35 kg/m2 with commodities (hypertension, diabetes, sleep apnoea, NASH).
Therefore, the majority of obese patients do not benefit from this procedure.
Recent advances in flexible endoluminal endoscopy now provide the tools for transoral endoscopic gastric volume reduction (ESG, endoscopic sleeve gastroplasty).
The gastric body is reduced by an endoscopic procedure involving suture plications.
This minimally invasive method may be a good therapeutic option to obtain a significant weight reduction in patients with moderate obesity or those with severe obesity and no indication for bariatric surgery (BMI between 35 and 40 kg/m2 without commodities).
In this context this study aims to identify predictive factors of weight loss following ESG and explore changes of metabolic parameters, metabolomic profiles and gut microbiota profiles.
This is a retro-prospective cohort study including patients with moderate obesity undergoing ECG between March 2017 and September 2023.
Clinical parameters (weight, high, BMI, weight fluctuations), serum metabolic parameters (standard lipid profile, lipoprotein levels, fasting plasma glucose, insulin levels, C-peptide levels, hemoglobin A1c) and liver function test parameters (standard biology, transient elastometry, Fibrotest®, Actitest®, abdominal ultrasound) are systematically collected for all patients before ESG and then at three- and twelve-month post-ESG.
Samples of serum, plasma, stools and saliva are also systematically collected for research purpose before ESG and then at three- and twelve-month post-ESG.
Each sample is stored at -80°C for subsequent analysis.
Metabolomic/lipidomic analysis will be used to quantify metabolite and lipid species in serum/plasma samples.
Metagenomic analysis will be used to characterise faecal and salivary microbiota profiles.
Study Type
Observational
Enrollment (Anticipated)
105
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cosmin VOICAN, MD, PhD
- Phone Number: +33 1 45 37 47 75
- Email: cosmin.voican@aphp.fr
Study Contact Backup
- Name: Gabriel PERLEMUTER, MD, PhD
- Phone Number: +33 1 45 37 47 75
- Email: gabriel.perlemuter@aphp.fr
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with moderate obesity undergoing endoscopic sleeve gastroplasty
Description
Inclusion Criteria:
- Age ≥18 years
- Patients giving their consent for the study
- Body mass index between 28 and 35 kg/m2 with co-morbid condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease or invalidating joint pain)
- No weigh loss following life-style changes
Exclusion Criteria:
- Antibiotic treatment during the three previous months
- Patients at risk of gastric cancer requiring regular endoscopic surveillance
- Gastric localization of Crohn disease
- Portal hypertension
- Severe hepatic or renal failure
- Ongoing peptic ulcer
- Severe associated disease
- History of previous bariatric surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Moderately obese patients
Moderately obese patients undergoing endoscopic sleeve gastroplasty
|
The data processed relates to patients cared for in the Hepato-gastroenterology and nutrition department of the Antoine Béclère Hospital at the Assistance Publique - Hôpitaux de Paris (AP-HP.
All of the clinical and paraclinical data are collected during the visits and entered into the OBPLUS database (database registered in the AP-HP register).
These data will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
The samples (plasma, serum, saliva, stool) collected during the samples taken as part of the patient's care were the subject of a biological collection "Liver, bile ducts and pancreas".
These samples will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum metabolite profile using widely targeted metabolomics according to weigh loss amount (less than 10% of total weight versus more than 10% of total weight loss at 12 months post-surgery)
Time Frame: Before endoscopic sleeve gastroplasty
|
A volume of 50 µl of serum/plasma will be used for analysis of serum metabolites using widely targeted metabolomics mass spectrometry.
|
Before endoscopic sleeve gastroplasty
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical parameters at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Weight expressed in kg, percentage of total weight loss and percentage of excessed weight loss will be analysed as they are systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Basic serum lipid profile at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Basic serum lipid profile will be analysed by spectrometry as they are systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Glycated hemoglobin at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Glycated hemoglobin expressed in % will be analysed as they are systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Insulin at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Insulin expressed in mUI/l will be analysed as it is systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
C peptide at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
C peptide expressed in µg/l will be analysed as it is systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Ferritin at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Ferritin expressed in µg/l will be analysed as it is systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Liver function test parameter Alanine transaminase (ALT) at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
ALT levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Liver function test parameter aspartate transaminase (AST) at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
AST levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Liver function test parameter Gamma-glutamyltransferase (GGT) at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
GGT levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Liver function test parameter Alkaline phosphatase (ALP) at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
ALP levels expressed in IU/l will be analysed as they are systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Liver fibrosis assessed by transient elastometry at baseline and then at 3 and 12 month post-intervention
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Transient elastometry expressed in kPa will be analysed as they are systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Liver steatosis assessed by controlled attenuation parameter (CAP) at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Controlled attenuation parameter expressed in dB/m will be analysed as they are systematically available in usual clinical practice.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Serum metabolites using widely targeted metabolomics at baseline and then at 3 and 12 month post-intervention.
Time Frame: Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
A volume of 50 µl of serum/plasma will be used for analysis of serum metabolites using widely targeted metabolomics by mass spectrometry.
|
Change from baseline (before endoscopic sleeve gastroplasty) to Month 3 and Month 12
|
Complications of endoscopic sleeve gastroplasty
Time Frame: During the first week post-endoscopic sleeve gastroplasty and at Month 3 and Month 12
|
Data on the potential complications (occurrence of perforation, bleeding, peritonitis and other infections, thrombo-embolic events and death) of endoscopic sleeve gastroplasty will be collected.
|
During the first week post-endoscopic sleeve gastroplasty and at Month 3 and Month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Cosmin VOICAN, MD, PhD, APHP, Antoine-Béclère Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2023
Primary Completion (Anticipated)
September 1, 2023
Study Completion (Anticipated)
October 1, 2023
Study Registration Dates
First Submitted
December 7, 2022
First Submitted That Met QC Criteria
February 20, 2023
First Posted (Actual)
March 1, 2023
Study Record Updates
Last Update Posted (Estimate)
March 6, 2023
Last Update Submitted That Met QC Criteria
March 3, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP230192
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on OBPLUS Clinical Database : data analysis
-
GEMA LEÓN BRAVOCompleted
-
Hospices Civils de LyonCompletedHIV | Pre-exposure ProphylaxisFrance
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruitingCrohn Disease | Ulcerative Colitis | Diverticulitis | Rectal Prolapse | Polyposis | Colorectal Tumor | Benign Colorectal TumorFrance
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruiting
-
Institut du Cancer de Montpellier - Val d'AurelleCompletedProstate Cancer | Bone Metastases | Hormone-resistant Prostate CancerFrance
-
University Hospital, MontpellierUnknown
-
Meyer Children's Hospital IRCCSRecruiting
-
GlaxoSmithKlineCompletedRotavirus Gastroenteritis | Nosocomial Rotavirus Gastroenteritis
-
GlaxoSmithKlineCompletedGastroenteritis | DiarrhoeaBrazil
-
University Hospital, Basel, SwitzerlandRecruiting